Expression and diagnostic potential of circulating miR-107, miR-134-5p, miR-149-5p, miR-370-3p, and miR-221 in prostate cancer and benign prostatic hyperplasia: a preliminary study
DOI:
https://doi.org/10.4081/aiua.2025.14585Keywords:
Prostate cancer, benign prostatic hyperplasia, miRNA, PSA, biomarkerAbstract
Background: MicroRNAs (miRNAs) have shown promise as diagnostic biomarkers for prostate cancer (PCa). This study aimed to evaluate the expression of miR-107, miR-134-5p, miR-149-5p, miR-370-3p, and miR-221 in whole blood to distinguish PCa from benign prostatic hyperplasia (BPH) and potentially reduce unnecessary biopsies.
Methods: Whole blood samples were collected from 20 PCa patients, 17 histologically-confirmed BPH patients (all with PSA >4 ng/mL), and 20 healthy controls over 60 years without symptoms suggesting prostatic disease and PSA <4 ng/mL. miRNA levels were quantified using qRT-PCR. Diagnostic potential was assessed via correlation analyses with clinical parameters and ROC curve evaluation. Statistical significance was set at p<0.05.
Results: miR-107, miR-134-5p, miR-149-5p, and miR-370-3p were significantly overexpressed in PCa patients compared to BPH (p<0.0001). ROC analysis identified miR-134-5p (AUC: 0.94) and miR-149-5p (AUC: 0.93) as strong predictors of PCa. Additionally, miR-149-5p showed a positive correlation with PSA levels (r = 0.2627, p<0.05).
Conclusions: This preliminary study demonstrated that miR-107, miR-134-5p, miR-149-5p, and miR-370-3p were significantly overexpressed in PCa patients compared to the BPH group. ROC analysis highlighted their diagnostic potential in distinguishing BPH from PCa. Despite the limited sample size, these findings provide early evidence to guide future research on the diagnostic value of miRNAs in prostate cancer.
Downloads
References
1. Vanacore D, Boccellino M, Rossetti S, et al. Micrornas in prostate cancer: an overview. Oncotarget. 2017; 8:50240-51.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
3. Abudoubari S, Bu K, Mei Y, et al. Preliminary study on miRNA in prostate cancer. World J Surg Oncol. 2023; 21:270.
4. Sekhoacha M, Riet K, Motloung P, et al. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules 2022; 7:5730.
5. Kohaar I, Petrovics G, Srivastava S. A rich array of prostate cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci. 2019; 20:1813.
6. Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023; 210:46-53.
7. Van Poppel H, Albreht T, Basu P, et al. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nat Rev Urol 2022;19:562-72.
8. Boehm BE, York ME, Petrovics G, et al. Biomarkers of aggressive prostate cancer at diagnosis. Int J Mol Sci. 2023; 24:2185.
9. Abramovic I, Ulamec M, Bojanac Katusic A, et al. MiRNA in prostate cancer: Challenges toward translation. Epigenomics 2020;12:543-58.
10. Esquela-Kerscher A, Slack FJ. Oncomirs -microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69.
11. Nayak B, Khan N, Garg H, et al. Role of miRNA-182 and miRNA-187 as potential biomarkers in prostate cancer and its cor relation with the staging of prostate cancer. Int Braz J Urol 2020;46:614-23.
12. Foj L, Ferrer F, Serra M, et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate 2016; 6:573-83. 13. Pełka K, Klicka K, Grzywa TM, et al. miR-96-5p, miR-134-5p,
miR-181b-5p and miR-200b-3p heterogenous expression in sites of prostate cancer versus benign prostate hyperplasia-Archival samples study. Histochem Cell Biol. 2021; 155:423-33.
14. Herrero-Aguayo V, Sáez-Martínez P, Jiménez-Vacas JM, et al. Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool. Mol Ther Nucleic Acids. 2022; 27:1164-78.
15. Pan JY, Zhang F, Sun CC, et al. miR-134: a human cancer suppressor? Mol Ther Nucleic Acids 2016; 6:140.
16. Chen Y, Zhao J, Luo Y, et al. Downregulated expression of miRNA-149 promotes apoptosis in side population cells sorted from the TSU prostate cancer cell line. Oncol Rep. 2016; 36:2587-600.
17. Shen Y, Zhao N, Zhao N, et al. Tumor-suppressive and oncogenic roles of microRNA-149-5p in human cancers. Int J Mol Sci. 2022; 23:10823.
18. Kiener M, Chen L, Krebs M, et al. MiR-221-5p regulates proliferation and migration in human prostate cancer cells and reduces tumor growth in vivo. BMC Cancer. 2019; 19:1-17.
19. Zhu J, Wang S, Zhang W, et al. Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network. Oncotarget. 2015; 6:43819.
20. Akan S, Ediz C, Temel MC, et al. Correlation of the grade group of prostate cancer according to the International Society of Urological Pathology (Isup) 2014 classification between prostate biopsy and radical prostatectomy specimens. Cancer Invest. 2021;
39:521-28.
21. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005; 29:1228-42.
22. Hernandez DJ, Nielsen ME, Han M, Partin AW. Contemporary evaluation of the D’Amico risk classification of prostate cancer. Urology. 2007; 70:931-5.
23. Livak JK, Schmittgen DT. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001; 25:402-8.
24. Bryant RJ, Pawlowski T, Catto JWF, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012;106:768-74.
25. Abramovic I, Vrhovec B, Skara L, et al. mir-182-5p and mir-375-3p have higher performance than psa in discriminating prostate cancer from benign prostate hyperplasia. Cancers (Basel) 2021;13:2068.
26. Liu CJ, Shen WG, Peng SY, et al. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int J Cancer. 2014; 134:811-21.
27. Su X, Zhang L, Li H, et al. MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion. Oncol Lett. 2017; 13:1932-8.
28. Puente-Rivera J, De la Rosa Pérez DA, Olvera SIN, et al. The circulating miR-107 as a potential biomarker up-regulated in castration-resistant prostate cancer. Noncoding RNA 2024;10:47.
29. Zhang X, Jin K, Luo JD, et al. MicroRNA-107 inhibits proliferation of prostate cancer cells by targeting cyclin E1. Neoplasma 2019;66:704.
30. Liang Y, Zhu D, Hou L, et al. MiR-107 confers chemoresistance to colorectal cancer by targeting calcium-binding protein 39. Br J Cancer. 2020; 122:705-14.
31. Chen HY, Lin YM, Chung HC, et al. miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res. 2012; 72:3631-41.
32. Wang S, Ma G, Zhu H, et al. miR-107 regulates tumor progression by targeting NF1 in gastric cancer. Sci Rep. 2016; 6:36531.
33. Ngalame NN, Tokar EJ, Person RJ, et al. Aberrant microRNA expression likely controls RAS oncogene activation during malignant transformation of human prostate epithelial and stem cells by arsenic. Toxicol Sci. 2014; 138:268-77.
34. Wang WL, Chatterjee N, Chittur SV, et al. Effects of 1α,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer 2011;10:1-15.
35. Ma J, Wei H, Li X, Qu X. Hsa-mir-149-5p suppresses prostate carcinoma malignancy by suppressing RGS17. Cancer Manag Res 2021; 13:2773-83.
36. Wang H, Yang L, Mi Y, et al. Diagnostic value of prostate-specific antigen combined with plasma miRNA-149 expression inpatients with prostate cancer based on experimental data and bioinformatics. Contrast Media Mol Imaging 2022;2022:6094409.
37. Shao N, Ma G, Zhang J, Zhu W. MIR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer. BMC Urol. 2018;18:14.
38. Agaoglu FY, Kovancilar M, Dizdar Y, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011;32:583-88.
39. Mercatelli N, Coppola V, Bonci D, et al. The inhibition of the highly expressed mir-221 and mir-222 impairs the growth of prostate carcinoma xenografts in mice. PLoS One 2008;3:e4029.
40. Leidinger P, Hart M, Backes C, et al. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status. Tumour Biol 2016;37:10177-85.
41. Wu Z, Sun H, Zeng W, et al. Upregulation of microRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. PLoS One 2012;7:e45825.
42. Luo G, Li G, Wan Z, et al. circITGA7 acts as a miR-370-3p sponge to suppress the proliferation of prostate cancer. J Oncol 2021;2021:8060389.
Downloads
Published
License
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
